title: Medicare reform and your practice: what you need to know.
abstract: Reimbursements for Medicare Part B physician-administered medications have been cut and will be further reduced in the years to come. Physician groups have supported the prescription benefit within the Medicare reform package. However, physician and patient advocacy groups alike are concerned about how other portions of the legislation will change the administration of Medicare Part B-covered drugs in the office setting. This article explores the payment changes built into the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, what the proponents and opposition have been saying, and how these changes will impact the practice of urology and patients with prostate cancer.
authors.affiliation: Triangle Urological Group, Pittsburgh, Pennsylvania 15212 , USA.
authors.forename: John Christopher
authors.initials: JC
authors.lastname: Lyne
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000191:economics; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D018166:Health Care Reform / Q000331:legislation & jurisprudence*; D006801:Humans; D008297:Male; D016345:Medicare Part B / Q000331:legislation & jurisprudence*; D020399:Practice Management / Q000191:economics*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014481:United States; D014572:Urology / Q000191:economics* / Q000458:organization & administration
chemical_list: D018931:Antineoplastic Agents, Hormonal